Skip to content

Oxytocin

PitocinSyntocinonThe love hormone
Approved

Evidence

Approved

Typical vial

2 mg

Route

3 routes

Status

United States

What it is

Approved as an injection to induce labour. The nasal spray sold for bonding and social anxiety rests on trials that have largely failed to replicate.

Reviewed 18 Aug 2026

Oxytocin is a nine-amino-acid hormone made in the hypothalamus. Its approved use is unglamorous and well established: intravenous oxytocin induces and augments labour and controls postpartum bleeding, given in hospital with continuous monitoring because too much causes dangerously strong contractions.

What people buy is the nasal spray, on the strength of a body of research from the late 2000s reporting that intranasal oxytocin increased trust, generosity and the reading of emotional expressions. Those studies drove a great deal of enthusiasm and a great deal of product.

That literature has not held up well. Large replication attempts have repeatedly failed to reproduce the social effects, and trials in autism, the most serious clinical application, have been largely negative, including a substantial multi-site study. There is also an unresolved question underneath all of it: how much intranasally administered oxytocin actually reaches the brain, and whether the doses used produce meaningful central concentrations at all.

How it works

Oxytocin binds oxytocin receptors, causing uterine smooth muscle to contract and milk to be released during breastfeeding. That peripheral physiology is well characterised and is what the approved use relies on.

In the brain, oxytocin is involved in social bonding, and animal work, particularly in voles, has shown clear effects on pair bonding. Whether that translates to humans at the doses used is the question the replication failures are about.

The delivery problem sits under everything: peptides do not cross the blood–brain barrier readily. Intranasal administration is meant to bypass it via the olfactory route, and how much actually arrives centrally is genuinely disputed.

It also has weak antidiuretic activity. Which is why very high or repeated doses can cause water retention and dangerously low sodium.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

  • Labour induction and postpartum haemorrhage

    Published review

    The approved use.

    EvidenceDecades of obstetric practice and trial evidence. Given intravenously with continuous fetal and uterine monitoring.

  • Social behaviour, trust and bonding

    Clinical trial

    What the nasal spray is sold for.

    EvidenceEarly studies reported effects on trust and emotion recognition. Large replication attempts have largely failed, and the effect sizes in the original literature show the pattern typical of publication bias.

  • Autism spectrum disorder

    Clinical trial

    The most seriously pursued clinical application.

    EvidenceA large multi-site randomised trial in children found no benefit on social withdrawal compared with placebo.

Regulatory status

Last reviewed 18 Aug 2026. Positions in this category change frequently, so we date the line.

United States

Approved by the FDA and EMA as an intravenous or intramuscular injection for obstetric use. Intranasal preparations sold for social or wellbeing purposes are compounded or research-chemical products with no approval for that use in the United States.

Identity and clearance

What the molecule is, and how long a dose stays measurable.

Molecule

Class
Cyclic nonapeptide hormone
Molecular weight
1007.2 Da
Length
9 amino acids

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 2 mg vialSourceStart this protocol
Doses used in the intranasal research literature40 mcg – 80 mcgA single administration in most study protocolsNasal24 to 48 IU is the range these studies used, expressed here in micrograms. Note that this is the dose whose effects have largely failed to replicate. It describes what was studied, not what we suggest.10–20 uClinical trialStart this
Obstetric use1 mcg – 20 mcgContinuous intravenous infusion, titrated to contractionsIntravenousTitrated in milliunits per minute against continuous fetal and uterine monitoring, because excessive stimulation causes uterine rupture and fetal distress. Nothing about this transfers outside a delivery suite.0.25–5 uPublished reviewStart this

The doses above in syringe units, for the vial you have:

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

Work out what to draw

Pre-filled with a 2 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Tool
Dose unit
Your syringe
01020304050607080901005 units0.05 mL

Draw to 5 units on a 1 mL U-100 syringe. That is 0.05 mL, containing 50 mcg of Oxytocin.

Concentration1mg / mL
Volume drawn0.05mL
Doses per vial40doses
Per unit10mcg / unit

Check5 units falls between the printed lines on a 1 mL U-100 syringe. Mixing with 1.6 mL of water instead would put this dose at 4 units.

BioAlmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects, the situations that need care, and the ones that mean stop.

Read before dosing

Reported effects

  • Generally well tolerated intranasally in study conditionsClinical trial

    In short research protocols

    Those protocols were single doses in supervised settings. Repeated daily use has not been characterised the same way.

  • Nasal irritation, headacheClinical trial

    Common with nasal use

  • Hyponatraemia and water retentionPublished review

    With high or repeated doses

    Oxytocin has weak antidiuretic activity. Severe low sodium causes confusion, seizures and can be fatal. This is the mechanism worth respecting with daily use.

  • Uterine hyperstimulationPublished review

    With obstetric use

    Why hospital administration is continuously monitored. Excessive contraction causes fetal distress and uterine rupture.

  • Blunted rather than enhanced social responsesClinical trial

    Reported in parts of the literature

    Some studies found increased in-group favouritism and out-group wariness rather than a general increase in trust. 'The love hormone' is a headline, not a summary.

When to stop

  • Headache with confusion, nausea or drowsiness. Possible low sodium. Seek urgent assessment.
  • Noticeable swelling or rapid weight gain.
  • Abdominal cramping, in anyone who could be pregnant. Seek urgent care.
  • Persistent nasal irritation or bleeding.

Interactions and situations that need care

  • Pregnancy, outside a delivery suiteAvoid

    Oxytocin causes uterine contraction. That is its approved purpose, given intravenously with continuous fetal monitoring because the margin between augmenting labour and causing harm is narrow. Self-administering it while pregnant is the most dangerous use of anything on this page.

  • Daily or repeated dosingUse caution

    The antidiuretic activity means water retention and low sodium accumulate with repeated dosing. The research protocols were single doses in supervised settings, so the safety impression they give does not extend to daily use.

  • Treating autismUse caution

    This was pursued seriously and a large multi-site randomised trial found no benefit. Families are marketed to on the strength of the early enthusiasm, not the result that followed it.

  • BreastfeedingUse caution

    Oxytocin triggers milk let-down. Effects on established feeding are not characterised for non-medical use.

What to expect

What the sources describe over time, and how confident anyone can be about it.

  • The obstetric use is real, approved medicine given in hospital with continuous monitoring.
  • The social effects that made it famous have largely failed to replicate at scale.
  • The autism trials, which were the serious clinical application, were negative.
  • How much intranasal oxytocin reaches the brain is genuinely disputed, which sits underneath every finding either way.
  • It has antidiuretic activity. Repeated dosing risks low sodium, which is the one way this becomes dangerous outside pregnancy.
  • 'The love hormone' is a headline. Parts of the literature found increased in-group favouritism rather than general warmth.

Storage and combinations

How to keep it, and what it does and does not go with.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are handled more than injectables and contaminate more easily.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it.

  • Clear, colourless solution

    Normal.

  • Cloudiness or particles

    Discard it.

Vocabulary on this page

IU
An international unit: a measure of biological activity, not of mass. How many milligrams an IU corresponds to depends entirely on the substance.
Unit
A mark printed on an insulin syringe. A unit is not a fixed volume. What it represents depends entirely on the syringe's scale.
Concentration
How much peptide there is in each millilitre of solution, once the vial has been reconstituted.
Evidence level
The category of human evidence behind a compound, from preclinical through to approved. Stated on every profile here as a category, not an adjective.
Peptide
A short chain of amino acids: the same building blocks as a protein, in a chain short enough to behave differently.
Protocol
One compound, with a dose, a frequency and a length: the plan, as opposed to what was actually taken.

The whole glossary →

Questions

Reader questions
Does the nasal spray actually do anything?
The early trust and bonding studies drove enormous interest and have largely failed to replicate. Trials in autism were negative. Underneath all of it is an unresolved question about how much gets to the brain by that route at all.
Is it dangerous?
In single research doses it was well tolerated. Two real risks. Low sodium from repeated dosing, and, far more seriously, uterine contractions, which make self-administration during pregnancy genuinely dangerous.

References

Everything on this page that came from a source, with the source.

  1. Oxytocin injection: FDA prescribing information

    US Food and Drug Administration, 2023 · Regulatory label

    Obstetric use · Intravenous infusion titrated in milliunits per minute

    Approved for induction and augmentation of labour and control of postpartum bleeding, with continuous fetal and uterine monitoring required. Warnings include uterine hyperstimulation and water intoxication with hyponatraemia from the antidiuretic effect.

  2. Intranasal oxytocin and social behaviour: replication failures and evidential value

    Psychological and neuroscience literature, 2017 · Replication studies and meta-analytic reviews

    Healthy adult volunteers across many studies · 24 to 48 IU intranasally

    Large replication attempts have repeatedly failed to reproduce reported effects on trust and emotion recognition. Analyses of the published literature show effect-size patterns consistent with publication bias, and central bioavailability by the intranasal route remains disputed.

  3. Intranasal oxytocin in children and adolescents with autism spectrum disorder

    New England Journal of Medicine, 2021 · Randomised, placebo-controlled, multi-site trial

    290 children and adolescents with autism spectrum disorder · Intranasal oxytocin, titrated, over 24 weeks

    No significant benefit over placebo on the primary measure of social withdrawal, and no significant differences on secondary measures.

    10.1056/NEJMoa2103583

Oxytocin compared with

Also compared with GHK-Cu, Ipamorelin, CJC-1295, Tesamorelin, MK-677, GHRP-2.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. No clinician reviews these pages.

Page last updated 18 Aug 2026